cyrilzakka/clinical-trials huggingface dataset:
The Effect of Oculomotor Exercises in the Warm-up on Forehand and Backhand Stroke Performance in Tennis Players

30 tennis players aged 12-18, will be included in the study. After their normal warm-up, the participants will make 30 forehand and 30 backhand strokes. Forehand and backhand stroke accuracy rate will be calculated. After a week, additional oculo-motor exercises will be included in the warm-up and the forehand and backhand stroke accuracy rate will be calculated again. The hypothesis that there will be an improvement in forehand and backhand stroke accuracy after oculo-motor exercises will be tested.

30 tennis players aged 12-18, who practice tennis for at least 6 hours a week and have been playing regularly for at least 1 year will be included in the study. The positive effect of oculo-motor exercises to be included in the pre-tennis warm-up program on stroke performance will be investigated. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight). Participants will be given a backhand and forehand stroke evaluation consisting of a total of 60 strokes, 30 forehand and 30 backhand. In the first evaluation, the participants will be asked to do their regular warm-up program. The area between the baseline line, service line and singles side line on the tennis court will be marked and two target areas will be created, one on the right and one on the left. Players will be asked to take one stroke parallel and one stroke diagonally, and they will be expected to hit the marked target areas. One week later there will be a second evaluation. In the second evaluation, oculo-motor exercises will be included in the participants' warm-up programs and the stroke evaluation will be repeated. The data obtained will be evaluated whether oculo-motor exercises have a positive effect on the forehand and backhand stroke rate.

Eligibility Criteria:
Inclusion Criteria:

* Being 12-18 years old
* Playing tennis for at least 6 hours a week
* Having been playing tennis for at least 1 year
* No visual defect (myopia, hyperopia, astigmatism)

Exclusion Criteria:

* Being under 12 years old
* Being over 18 years old
* Playing tennis for less than 6 hours a week
* The duration of playing tennis is less than 1 year
* Having visual impairment (myopia, hyperopia, astigmatism)
Bolus Pouch Feed Study

The primary aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life. Secondary aims are to assess ease of use, liking, compliance, gastrointestinal tolerance, nutrient intake, anthropometric changes and safety.

Bolus enteral tube feeding (termed 'bolus feeding') is an increasingly common method of providing nutritional support to home enterally tube fed (HETF) patients, particularly those who are more active and/or require greater flexibility in their feeding regimen. However, current methods of bolus feeding are complex to administer, messy, may be unhygienic, and require and lead to a significant amount of plastic waste. Therefore, there is a clear need for a simpler and optimised way to provide bolus feeds. The aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life, ease of use, liking, compliance, gastrointestinal tolerance, nutritional intake, anthropometry and safety. This is a prospective, longitudinal, 28-day intervention study with a 7-day baseline period.

Eligibility Criteria:
Inclusion Criteria:

* ≥16 years of age
* Using or requiring an enteral tube feed as part of nutritional management plan
* Using or about to use bolus tube feeding methods at least once daily
* Expected to receive at least 400 kcal/day from the intervention feed
* Written or electronic informed consent from patient, or verbally given consent countersigned by a witness for those physically unable to sign.

Exclusion Criteria:

* Parenteral nutrition contributing more than 70% of total energy requirements
* Patients with major hepatic dysfunction (i.e., decompensated liver disease)
* Patients with major renal dysfunction \[i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)\]
* Patients receiving inpatient care
* Participation in other clinical intervention studies within 2 weeks of this study
* Adults lacking mental capacity to consent
* Allergy to any study product ingredients
* Investigator concern regarding ability or willingness of patient to comply with the study requirements.
Oxford UKA and HTO Post-market Clinical Study

The purpose of this study is to compare the performance and safety of medial UKA and HTO in the treatment of AMOA in term of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome.

The purpose of this study is to compare the outcomes of medial UKA and HTO in the treatment of AMOA by investigating the performance of these 2 procedures in terms of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome, then identify factors associated with better clinical performance. It is aimed to provide evidence-based guidelines for selecting the appropriate procedure in managing AMOA in Chinese population based on the findings of this study.

The secondary endpoints will include:

1. Pain Numerical Rating Scale (NRS)
2. SF-12 Health Survey
3. Radiographic assessment includes pre-op and post-op mechanical femorotibial angle (mFTA), patella height, patellofemoral medial and lateral articular surfaces, and displacement angle of patella
4. Range of motion
5. Adverse event rate and classification (including complication)
6. Operating time
7. Total blood loss (BRECHER formula)
8. Revision rate

Health economic outcomes based on hospital discharge days, recovery time, physiotherapy and complications/ reoperations will also be analyzed.

Eligibility Criteria:
Inclusion Criteria:

1. Patient is aged 18 to 85 years old, inclusive;
2. Patients who diagnosed with AMOA of the knee, and have undergone Open Wedge HTO, or primary unilateral partial knee arthroplasty with Oxford Partial Knee with Microplasty® instrumentation in accordance to indications of UKA and the following radiographic assessments in the knee joint:

   * exposed bone on both the femur and tibia in the medial compartment.
   * functionally intact ACL
   * full thickness lateral cartilage (ignore osteophytes)
   * functionally normal MCL: correctable deformity (normal medial opening)
   * acceptable patellofemoral joint: normal, medial facet OA with or without bone loss, lateral facet OA without bone loss.
3. UKA or HTO procedure completed one year prior to study participation;
4. Patient provides written informed consent by signing and dating the Institutional Review Board/Ethics Committee (IRB/EC) approved informed consent form.

Exclusion Criteria:

1. Has undergone UKA but met any of the contraindications included in the product labeling of Oxford Partial Knee system;
2. Has rheumatoid arthritis or other forms of inflammatory joint disease;
3. Uncooperative or with neurologic disorders who are incapable of following directions;
4. Has a diagnosed systemic disease that could affect his/her safety or the study outcome;
5. Anterior cruciate ligament and posterior cruciate ligament injury, collateral ligament instability;
6. Known to be pregnant;
7. Prisoner or known alcohol / drug abuser.
Detection Cell Free DNA in Lung Cancer Patients

third generation of EGFR-TKIs is the newest target therapy for NSCLC. However, we did not known the specific mechanisms for those non-responders and patients grow resistance.Next generation sequencing is current the most sensitive and specific method to exam gene mutation, diversion etc.

By consistently detect the cf-DNA, we could possibly find out the mechanisms of response and resistance.

Study backgroud: third generation of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the newest target therapy for non small cell lung cancer (NSCLC). Two major study published in NEJM show that the overall response rate is about 60%-70%, with a progression free survival about 10 months. However, we did not known the specific mechanisms for those non-responders and patients grow resistance.

Next generation sequencing is current the most sensitive and specific method to exam gene mutation, diversion etc. By consistently detect the cf-DNA, we could possibly find out the mechanisms of response and resistance.

Eligible patients received 3rd generation EGFR-TKIs (AZD9291 and AVITINIB) were enrolled into this study. Tumor tissue sample within 6 months, and 10ml periphereal blood samples were collected at baseline. After treatment initiation, 10ml periphereal blood would be collected at every image testing time point until disease progression. Blood samples will be draw using EDTA tube and centerfuged within 2 hours and store in -80 refrigerator.

NGS testing will cover target genes of NSCLC.

Eligibility Criteria:
Inclusion Criteria:

* pathologically confirmed non small cell lung cancer.
* harboured with positive EGFR mutation (19 exon deletion, L858R、G719X、L861Q mutation)
* reliable patients history data.

Exclusion Criteria:

* pathologically not confirmed non small cell lung cancer.
* multiple primary cancer.
Lyon Uveitis Study

Uveitis or inflammation of the uveal tract results from a heterogeneous collection of disorders of varying etiologies and pathogenic mechanisms. Uveitis is relatively frequent in industrial countries with an estimation of 115 cases for 100 000 persons and is associated with a blindness risk of 10%. Causes of uveitis can be related to different etiologies (infectious, inflammatory or general inflammatory diseases). Therapeutic care is based on ophthalmologic and systemic diagnosis and treatment strategy depends on the severity of inflammation.

The main objective of the Lyon uveitis study is to analyze the uveitis ophthalmologic etiology and diagnostic and therapeutic care of the patients. This study is proposed to all patients diagnosed for uveitis and referred to the Department of Internal Medicine of the Croix Rousse hospital, Lyon, france for etiologic diagnosis or treatment.

Analysis of i) patients' characteristics, ii) the relevance of complementary exams to determine the uveitis etiology, iii) treatment used.

This study will allow a better characterization of the disease on diagnosis practices and therapeutic care.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of uveitis
* First consultation in the Department of Internal Medicine at the Croix-Rousse hospital, Lyon, France

Exclusion Criteria:

-
Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI

This small study will investigate the feasibility of using multi-parametric MRI to introduce and support adaptive radiotherapy treatments for high-risk prostate cancer.

Mount Vernon Cancer Centre at East and North Hertfordshire NHS Trust offers patients with certain cancers a treatment called adaptive radiotherapy. The aim of adaptive radiotherapy is to respond to physical changes that occur during treatment to ensure the radiation continues to be directed at the cancer and to minimise the amount of healthy tissue treated. For example, if tumour shrinkage or weight loss occurs during head and neck radiotherapy the patient may have a repeat CT scan and a new radiotherapy treatment plan after a few weeks of treatment. For patients with cancer of the bladder or cervix changes in bladder and uterus size and position can be predicted allowing the prospective creation of three radiotherapy treatment plans, each day the best fitting plan, i.e. the one that closely covers the tumour whilst giving minimal dose to normal tissues, is selected and used for treatment, this is known as plan-of-the-day adaptive radiotherapy.

Small changes in shape and position of the prostate occur but are generally the result of rectal changes which cannot be predicted, consequently adaptive radiotherapy based on physical change is not possible for prostate cancer treatments. However, recent literature suggests that magnetic resonance imaging (MRI) can detect changes within the prostate in response to radiotherapy, some studies have seen changes as early as the second week of radiotherapy treatment. A feasibility study to investigate if these changes can support radiotherapy treatment plan adaption for prostate cancer treatments is proposed, whether the plan can be adapted to give a higher treatment dose to any areas of the prostate that show poor response to radiotherapy without increasing bowel and bladder dose is of particular interest. The treatment for patients who participate in the study would not be changed but the results may help to personalise and improve the treatment of future patients.

Eligibility Criteria:
Inclusion Criteria:

1. New diagnosis of high-risk prostate cancer: any of:

   1. Gleason score of 8, 9 or 10
   2. PSA \> 20
   3. T3/4
2. Patient due to receive androgen deprivation therapy (ADT)
3. Prescribed 78Gy/39# external beam radiotherapy
4. Measurable dominant intraprostatic tumour on diagnostic imaging of at least 10mm diameter
5. ≥18 years of age
6. ECOG performance status of 0-1
7. Informed, written and witnessed consent to participate is required.

Exclusion Criteria:

1. Patients who are not due to receive androgen deprivation therapy (ADT)
2. Any contraindication to MRI scanning including contraindication to MRI contrast agents
3. Previous radiotherapy to the pelvis
4. Any physical or social reasons that would make attendance for additional visits impossible.
5. Any patient with or planned for prostate fiducial markers.
6. Unable to give informed consent.
7. Patients currently enrolled in an interventional clinical trial.
Kinesio Taping in Subjects With Myofascial Pain Syndrome: a Randomized Controlled Trial

Musculoskeletal dysfunction is considered as a major public health problem affecting about one third of the adult population. Myofascial pain syndrome (MPS) characterized by myofacial trigger points as well as fascia tenderness are thought to be the main cause of musculoskeletal dysfunction. The aim of the treatment for musculoskeletal dysfunction is to reduce pain and restore normal function. Clinically, some evidence supports the application of kinesio tape in these patients. The underlying mechanism, however, is not clear. The investigators goal was to validate proposed mechanism of kinesio tape in these patients. The primary outcome are muscle stiffness, pain intensity and sensitivity.


Eligibility Criteria:
Inclusion Criteria:

* age between 20 and 60 years
* shoulder or neck pain corresponding with the area covered by the upper trapezius muscle
* Trigger point (taut band) in the upper trapezius muscle

Exclusion Criteria:

* diagnosis of fibromyalgia syndrome
* having undergone myofascial therapy within the past month before the study
* history of cervical spine or shoulder surgery
* previous history of a whiplash injury;
* diagnosis of cervical radiculopathy or myelopathy;
* taking medicine that might change the pain intensity or pain threshold, such as analgesics, sedatives, substance abuse (including alcohol, narcotics);
* a cognitive impairment that would prevent them from being able to understand and/or participate fully in the intervention or the measures.
Prophylactic Anti-aRrhythmic Therapy with Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest with Initial Shockable Rhythm

To determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and/or severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and/or ventricular tachycardia requiring intervention including re-arrest)


Eligibility Criteria:
Inclusion Criteria:

1. Patient aged ≥ 18 years
2. Admitted in intensive care unit
3. Out-of-hospital cardiac arrest with initial shockable rhythm
4. Presumed cardiac or unknown cause
5. Delay between ROSC and screening for randomisation \< 6 hours
6. Informed consent from the patient or a surrogate or deferred consent
7. Affiliated to or benefiting from a social insurance

Exclusion Criteria:

1. Cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed)
2. Indication for amiodarone decided by the physician at ICU admission
3. No central venous catheter available for continuous infusion of amidoarone
4. Thyroid disease under treatment
5. History of cardiac conduction disorders, not treated by permanent pacemaker
6. Any contra indication to amiodarone treatment
7. Refractory ventricular arrhythmia or electrical storm
8. Need for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) at admission
9. Known limitations in therapy and Do Not Resuscitate-order
10. Moribund patient due to pre-arrest history (estimated life expectancy \< 3 months)
11. Pregnant or breastfeeding women
12. Patient needing a nadolol treatment due to QT long syndrome or catecholaminergic polymorphic ventricular tachycardia
13. Patient with known pulmonary fibrosis
14. Patient with known interstitial lung disease
Tender Loving Care for Recurrent Pregnancy Loss

The goal of this investigational study is to evaluate participation in a weekly, interactive, tender loving care messaging platform impact on pregnancy outcomes in patients with recurrent pregnancy loss.

The main questions it aims to answer are: (1) does participation in weekly, interactive tender loving care messages increase live birth rates in patients with recurrent pregnancy loss? (2) Does participation in weekly, interactive tender loving care messages increase patients' quality of life? Does participation in weekly, interactive tender loving care messages decrease patients' depressive symptoms?

Participants will be asked to interact with weekly messages providing prenatal counseling and support. Additionally, patients will be asked to complete the fertility quality of life survey several times over the course of the pregnancy.

Participants will be asked to interact with weekly messages providing prenatal counseling and support. Additionally, patients will be asked to complete the fertility quality of life survey several times over the course of the pregnancy.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant individuals receiving their prenatal care at WRNMMC
* Able to speak and understand English
* Less than or equal to 10+0 weeks gestation by last menstrual period (LMP) or dating ultrasound at the time of enrollment
* At least two prior pregnancy losses. Pregnancy losses must be confirmed with laboratory criteria confirming a positive pregnancy test in the military electronic medical record with subsequent resolution (resolution may be reported by patient), or with ultrasound criteria demonstrating an intrauterine gestational sac with subsequent resolution (resolution may be reported by patient).

Exclusion Criteria:

* Age less than 18 years and older than 44 at time of enrollment
* Unable to speak or understand English
* Current smoker or tobacco use within 30 days
* History of uterine anomaly, coagulopathy, balanced translocation, endometrial polyps, submucosal fibroids, pathology confirmed acute or chronic endometritis, hydrosalpinx, history of Asherman syndrome, poorly controlled endocrinopathies, HIV infection
* History of gonadotoxic therapy or cancerous condition of the female reproductive tract
* Suspicion for or confirmation of an ectopic pregnancy
Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone

The planned study has two purposes:

1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year.
2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .


Eligibility Criteria:
Inclusion Criteria:

* Aged between 70 and 80 years

Exclusion Criteria:

* Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block),
* Treatment with beta-blockers, NSAIDs or cholinergic agonists,
* Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any excipients used in the formulation,
* Gastric and duodenal ulcer,
* Severe renal and hepatic impairment,
* Urinary congestion (prostatic hypertrophy),
* Obstructive pulmonary disease (bronchial asthma);
Coordinated Reset Deep Brain Stimulation for Essential Tremor

Deep brain stimulation (DBS) is a surgical procedure for the treatment of Essential Tremor (ET). A novel approach to current DBS approaches is called coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS that uses continuous high amplitude, high frequency stimulation. This study will evaluate the feasibility, safety and short-term efficacy of thalamic CR-DBS in upper extremity ET. The goal of this study is to evaluate the safety and short-term efficacy of thalamic CR- DBS in ET, including the acute (during CR-DBS) and carryover (following DBS cessation) effects, and compare these to those induced by clinically optimized T-DBS. To achieve our goal, a low-risk, two-phase clinical study will be conducted in patients with upper extremity (UE) ET. The first aim is to identify the spatial location and peak frequency of tremor related oscillatory activities in VIM (Phase I). The second aim is to compare the acute effects of thalamic CR-DBS to clinically optimized T-DBS (Phase II).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Essential Tremor (ET)
* Age of 21 or over
* Will be implanted with Boston Scientific Vercise Rechargeable Genus deep brain stimulation (DBS) system
* 7 Tesla (7T) MRI pre-operative scan under Noam Harel PhD's (Center for Magnetic Research (University of Minnesota IRB #1210M22183) protocol "Imaging of DBS targets at 7T MRI"
* Planned post-operative CT scan

Exclusion Criteria:

* History of musculoskeletal disorders that affect movement of the limbs or gait
* Other significant neurological disorder
* History of dementia or cognitive impairment (Mini-Mental Score \&lt; 26)
* Significant psychiatric disease
* On medication that could cause tremor
* Prior brain surgery
* Pregnant women
* Evidence of non-ET central nervous system disease or injury for at least three (3) months prior to implantation
* Any suspicion of Parkinsonian tremor, including presence of Parkinsonian features such as bradykinesia, rigidity, or postural instability
* Other significant medical disorder that could impede study participation